Clinical Trial Update: A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants [Phase 1]

View source ↗

Summary

A Phase 1 single ascending dose study of DT-216P2 in healthy participants with Friedreich Ataxia as the target condition; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• DT-216P2

Snippet

Sponsor: Design Therapeutics, Inc. | Conditions: Friedreich Ataxia | Phase 1 | Status: NOT_YET_RECRUITING